|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 556 active entries
- / P. O. Box 1, UNSW (Syd) Kensington NSW 2033
Toll free: +011-604-941-9022
Our Seco-Steroidal Chemistry to you:
Our projects are exlusively of our own proprietary and meant for informations purposes only. This began with our Principal Investigators work earlier in the late '70s on steroidal chemistry with plant product Lanosterol at Simon Fraser University BC CANADA which led later to our own didactions (see:  below) on drug therapy using VitD metabolism as it applies to chronic or acute inflammation and related occupational-related or life-style diseases such as diabetes type2, atherosclerosis or heart disease and certain if not most cancers (e. g. breast and colon).
 Seco-steroidal drugs to effect receptors on the cell membrane involved to therapeutically address cholesterol uptake at the gut level and metabolically, post-absorptively (readily on the market).
 Seco-steroidal drugs to effect antagonism of feed-back inhibition (FBI) VitD effector functions and prolong their active state as with our Retonobionols (R) to help control of prevent the prevalence of cancers and other chronic inflammatory disease conditions of the body.
 Steroidal analogues to compete with and control, via this pharma, the esterifications and storage of cholesterol in shell eggs with poultry. This proposal further expands on (see:  above) the theme of cholesterol whole-body metabolism and its emptying into the digestive tract through bile juice from the duct.
 Steroidal analogues in plant secoundary alkaloid derivatives that bind to mother cell mitotic spindle fibres and prevent pollination in genetically manipulated biosafe plant life.
A Skye Blue Company
Last update of this entry: May 01, 2018